The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: The dal-ACUTE randomized trial

European Heart Journal

Volumn 35, Issue 27, 2014, Pages 1792-1800

  Ray, Kausik K ^a   Ditmarsch, Marc ^b   Kallend, David ^b   Niesor, Eric J ^b   Suchankova, Gabriela ^b   Upmanyu, Ruchi ^c   Anzures Cabrera, Judith ^c   Lehnert, Valerie ^b   Pauly Evers, Meike ^b   Holme, Ingar ^d   ŠtÍásek, Josef ^e   Van Hessen, Maarten W J ^f   Jones, Peter ^g  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^f GROENE HART HOSPITAL   (Netherlands)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Coronary disease; Lipids; Lipoproteins

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; PLACEBO; ABC TRANSPORTER A1; ABCA1 PROTEIN, HUMAN; APOLIPOPROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CETP PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; THIOL DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ANGINA, UNSTABLE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; LIPID METABOLISM; METABOLISM; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PHASE 3 CLINICAL TRIAL;

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; ATP BINDING CASSETTE TRANSPORTER 1; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIPID METABOLISM; LIPOPROTEINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SULFHYDRYL COMPOUNDS;

EID: 84904552078     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu105     Document Type: Article

References (27)

1. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 2010;55:1283-1299.
2. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL: guardian angel of the arterial wall?. Nat Clin Pract Cardiovasc Med 2006;3:144-153.
3. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
4. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011;22:176-185.
5. Khera AV, Cuchel M, Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-135.
6. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de FU, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de BA, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, Konig IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schafer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012;380:572-580.
7. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122.
8. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-2099.
9. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009;50(Suppl):S145- S149.
10. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. Circulation 2012;126: 2020-2035.
11. Miida T, Miyazaki O, Nakamura Y, Hirayama S, Hanyu O, Fukamachi I, Okada M. Ana-lytical performance of a sandwich enzyme immunoassay for pre beta 1-HDL in stabilized plasma. J Lipid Res 2003;44:645-650.
12. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009;158: 896-901.
13. Dullaart RP, de Boer JF, Annema W, Tietge UJ. The inverse relation of HDL anti-oxidative functionality with serum amyloid a is lost in metabolic syndrome subjects. Obesity (Silver Spring) 2013;21:361-366.
14. Niesor EJ, Magg C, Ogawa N, Okamoto H, von der ME, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, Huber W, Thoma R, Pflieger P, Kakutani M, Takahashi D, Dernick G, Maugeais C. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010;51:3443-3454.
15. Maugeais C, Perez A, von der ME, Magg C, Pflieger P, Niesor EJ. Evidence for a role of CETP in HDL remodeling and cholesterol efflux: Role of cysteine 13 of CETP. Biochim Biophys Acta 2013;1831:1644-1650.
16. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL fromCETP-deficient subjects shows enhanced abilityto promote cholesterol efflux from macrophages inanapoE-and ABCG1-dependent pathway. J Clin Invest 2006;116:1435-1442.
17. Zhang B, Fan P, Shimoji E, Xu H, Takeuchi K, Bian C, Saku K. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol 2004;24: 1910-1915.
18. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013;33:1696-1705.
19. Sankaranarayanan S, Llera-Moya M, Drazul-Schrader D, Asztalos BF, Weibel GL, Rothblat GH. Importance of macrophage cholesterol content on the flux of cholesterol mass. J Lipid Res 2010;51:3243-3249.
20. de la Llera MM, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, Tabita-Martinez J, Wolfe ML, Badellino K, Pruscino L, Mehta NN, Asztalos BF, Reilly MP. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 2012;222:390-394.
21. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314-324.
22. Sala F, Catapano AL, Norata GD. High density lipoproteins and atherosclerosis: emerging aspects. J Geriatr Cardiol 2012;9:401-407.
23. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW III, Sisk CM, Mitchel Y, Pasternak RC. Efficacy and safetyofthe cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009;157:352-360.
24. Chenevard R, Hurlimann D, Spieker L, Bechir M, Enseleit F, Hermann M, Flammer AJ, Sudano I, Corti R, Luscher TF, Noll G, Ruschitzka F. Reconstituted HDLin acute coronary syndromes. Cardiovasc Ther 2012;30:e51-e57.
25. Niesor EJ, Schwartz GG, Suchankova G, Benghozi R, Abt M, Kallend D. Statin decrease in ABC transporter A1 expression via miR33 induction may counteract cholesterol efflux by high-density lipoproteins raised with the cholesteryl ester transfer protein modulator dalcetrapib. Atherosclerosis 2014. In press.
26. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-2300.
27. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675-1682.